




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :  A61F 2/06		A1	(11) International Publication Number:  WO 00/15147
			(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/20714		1111 Crestview Way, Goshen, KY 40026 (US). GRIFFIN, Mark [US/US]; Apartment 3, 4113 Bridgewood Court, Louisville, KY 40241 (US). WOLF, Scott, J. [US/US]; 2501 Irvine Avenue South, Minneapolis, MN 55405 (US). WILK, Peter, J. [US/US]; 185 West End Avenue, New York, NY 10023 (US). SCHMELTER, Jay, W. [US/US]; 6090 Annapolis Lane North, Plymouth, MN 55466 (US). FURNISH, Simon, M. [US/US]; 2429 Longest Avenue, Louisville, KY 40204 (US). RENATI, Richard, J. [US/US]; * (US). MELSKY, Gerald [US/US]; * (US). GUILES, Marvin [US/US]; * (US).	
(22) International Filing Date: 10 September 1999 (10.09.99)			
(30) Priority Data:			
60/099,767 10 September 1998 (10.09.98) US 60/104,397 15 October 1998 (15.10.98) US 60/147,202 4 August 1999 (04.08.99) US 60/147,218 4 August 1999 (04.08.99) US 09/369,048 4 August 1999 (04.08.99) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application		(74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, LLP, Sixteenth Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).	
US 09/369,048 (CIP) Filed on 4 August 1999 (04.08.99)			
(71) Applicant (for all designated States except US): PERCARDIA, INC. [US/US]; Suite 434, 20 Trafalgar Square, Nashua, NH 03063 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): PHELPS, David, Y. [US/US]; 904 Shady Lane, Louisville, KY 40223 (US). FURNISH, Greg, R. [US/US]; 2614 Top Hill Road, Louisville, KY 40206 (US). HALL, Todd, A. [US/US];		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: TMR SHUNT



## (57) Abstract

A conduit is provided to provide a bypass around a blockage in the coronary artery. The conduit is adapted to be positioned in the myocardium or heart wall to provide a passage for blood to flow between a chamber of the heart such as the left ventricle and the coronary artery, distal to the blockage. The stent is self-expanding or uses a balloon to expand the stent in the heart wall. Various attachment means are provided to anchor the stent and prevent its migration. In one embodiment, a conduit is provided having a distal top which is more preferably a ball top, wire top, flare top or flip-down top. These top configurations anchor the shunt at one end in the coronary artery.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## TMR SHUNT

Field of the Invention

The present invention relates to an apparatus for bypassing a blocked blood vessel segment, and, more particularly, to a conduit or stent positioned between the coronary artery or other blocked vessel and a chamber of the heart, such as the left ventricle of the heart, to bypass a blocked segment of the coronary artery or other blood vessel.

Background of the Invention

Coronary artery disease is a major problem in the U.S. and throughout the world. Coronary arteries as well as other blood vessels frequently become clogged with plaque, which at the very least impairs the efficiency of the heart's pumping action, and can lead to heart attack and death. In some cases, these arteries can be unblocked through non-invasive techniques such as balloon angioplasty. In more difficult cases, a bypass of the blocked vessel is necessary.

In a bypass operation, one or more venous segments are inserted between the aorta and the coronary artery. The inserted venous segments or transplants act as a bypass of the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of blood to the heart. More than 500,000 bypass procedures are performed in the U.S. every year.

Such coronary artery bypass surgery, however, is a very intrusive procedure that is expensive, time-consuming and traumatic to the patient. The operation requires an incision through the patient's sternum (sternotomy), and that the patient be placed on a bypass pump so that the heart can be operated on while not beating. A vein graft is harvested from the patient's leg, another highly invasive procedure, and a delicate surgical procedure is required to piece the bypass graft to the coronary artery (anastomosis). Hospital stays subsequent to the surgery and convalescence are prolonged.

As mentioned above, another conventional treatment is percutaneous transluminal coronary angioplasty (PTCA) or other types of angioplasty. However, such vascular treatments are not always indicated due to the type or location of the blockage, or due to the risk of emboli.

Thus, there is a need for an improved bypass system which is less traumatic to the patient.

Summary of the Invention

5

The preferred embodiments of the present invention address the need in the previous technology by providing a bypass system that avoids the sternotomy and other intrusive procedures normally associated with coronary bypass surgery. These embodiments also free the surgeon from the multiple anastomoses necessary in the current process.

10

15

The preferred device provides a shunt for diverting blood directly from a chamber in the heart, such as the left ventricle, to the coronary artery, distal to the blockage, therefore bypassing the blocked portion of the vessel. The shunt comprises a stent or conduit adapted to be positioned in the heart wall or myocardium between a chamber in the heart such as the left ventricle and the coronary artery that allows for the direct passage of blood therethrough. As used herein, the terms "stent" and "conduit" are interchangeable, and refer to a device that allows for the passage of blood therethrough. The terms "myocardium" and "heart wall" are also used interchangeably. In addition, although the left ventricle is referred to throughout the description, it should be understood that the conduit described herein can be used to provide a passageway for the flow of blood from any heart chamber, not only the left ventricle.

20

25

The stent device is delivered either externally or internally through the coronary artery to a position distal to the blockage. At that position, the coronary artery, the myocardium and the wall of the left ventricle are pierced to provide a channel completely through from the coronary artery to the left ventricle of the heart. The stent is then positioned in the channel to provide a permanent passage for blood to flow between the left ventricle of the heart and the coronary artery, distal to the blockage. The stent is sized so that one open end is positioned within the coronary artery, while the other open end is positioned in the left ventricle. The hollow lumen of the stent provides a passage for the flow of blood.

30

The stent can be self-expandable or expanded by means of a balloon or similar device, and can be provided with various means to anchor it in position, such as expandable legs, hooks, barbs, flanges, collars, loops, wires, flares, suture holes and the like. The anchoring means can be adapted to anchor the conduit in the heart wall, or alternatively, in the coronary artery. The stent can be formed from a plurality of rings, which can be connected to provide stability. The stent can include a valve in its interior, and can also be used to deliver drugs or other pharmaceutical compounds directly into the myocardium and the coronary circulation.

5

Briefly stated, the methods and apparatus described and illustrated herein generally relate to direct coronary revascularization, wherein a conduit or opening is provided from the left ventricle to the coronary artery, oftentimes the left anterior descending (LAD), to provide blood flow directly therethrough. The conduit of the preferred embodiments has a distal top which is more preferably a ball top, wire top, flare top or flip-down top. These top configurations anchor the shunt at one end in the coronary artery.

Brief Description of the Drawings

FIGURE 1A is a cross-sectional view of a human heart, aorta and coronary artery.

FIGURE 1B is a side view of one embodiment of an expandable stent and the balloon catheter used for stent delivery.

FIGURE 2 is a side view of the stent of FIGURE 1B mounted on the distal end of the catheter for delivery into the myocardium, with the coronary artery and myocardium shown cut-away.

FIGURE 3 is a side view of the distal end of the stent/catheter assembly of FIGURE 1B positioned in the myocardium, with the coronary artery and myocardium shown cut-away.

FIGURE 4 is a cross-sectional side view of the stent of FIGURE 1B positioned within the myocardium after removal of the catheter used for delivery.

FIGURE 5 is a side view of another embodiment of the stent and the catheter used for stent delivery.

FIGURE 6 is a cross-sectional side view of the catheter and puncture device used to introduce the self-expanding stent of FIGURE 5 into the myocardium.

FIGURE 7 is a cross-sectional side view of the stent/catheter assembly of FIGURE 5 positioned in the myocardium.

FIGURE 8 is a side view of the self-expanding stent of FIGURE 5 positioned within the myocardium after removal of the catheter and puncture device, with the coronary artery and myocardium shown cut-away.

FIGURE 9 is a perspective view of another embodiment of the stent having expandable legs, showing the stent mounted on the distal end of the introducer catheter.

FIGURE 10 is a perspective view of the stent of FIGURE 9, showing the distal end of the introducer catheter pushed forward to allow the legs of the stent to expand.

**FIGURE 11** is a perspective view of the stent of **FIGURE 9**, showing the legs of the stent in an expanded position.

**FIGURE 12** is a side view of another embodiment of the stent positioned within the myocardium, with the coronary artery and myocardium shown cut-away.

5       **FIGURE 13** is a side view of a biodegradable stent positioned within the myocardium, with the coronary artery and myocardium shown cut-away.

**FIGURE 14** is a side view of a catheter and puncture device used to introduce a bulkhead stent into the myocardium, with the coronary artery and myocardium shown cut-away.

10      **FIGURE 15** is a side view of the stent/catheter assembly of **FIGURE 14** positioned in the myocardium, with the coronary artery and myocardium shown cut-away.

**FIGURES 16-19** are progressive side views of the stent/catheter assembly of **FIGURE 14**, showing the bulkhead stent being deployed into the myocardium.

15      **FIGURES 20** and **21** are enlarged views of **FIGURES 18** and **19**, respectively, showing the bulkhead stent being deployed into the myocardium.

**FIGURE 22** is a perspective view of a ring of a bulkhead stent in a loaded configuration

20      **FIGURE 23** is a perspective view of a ring of a bulkhead stent in an inserted configuration.

**FIGURE 24** is a perspective view of a bulkhead stent within a delivery catheter, showing the rings of the bulkhead stent being inserted.

**FIGURE 25** is a perspective view of a bulkhead stent, with the rings of the stent in loaded and inserted configurations.

25      **FIGURE 26** is a perspective view of an inserter device used to insert a bulkhead stent.

**FIGURE 27A** is a schematic, cross-sectional view of the human heart, showing a catheter used to form a channel through the myocardium and into the left ventricle inserted into the coronary artery.

30      **FIGURE 27B** is an enlarged view of the distal end of the catheter and the channel through the myocardium in **FIGURE 27A**.

**FIGURE 28** is a schematic, cross-sectional view of a stent delivery catheter positioned inside the channel formed in the myocardium.

35      **FIGURE 29** is a schematic, partial cross-sectional view of a self-expanding spring stent being positioned in the channel formed in the myocardium.

**FIGURE 30** is a schematic, partial cross-sectional view of the self-expanding stent deployed within the myocardium.

**FIGURE 31** is a perspective view of another embodiment of a stent having retention members which maintain the position of the stent.

5       **FIGURE 32** is a schematic, cross-sectional view of a human heart, showing a conduit in the myocardium of the heart for forming a bypass shunt between the left ventricle and a coronary artery.

**FIGURE 33A** is a side view of a wire top shunt according to one embodiment of the present invention.

10      **FIGURE 33B** is a side view of a wire top shunt according to another embodiment of the present invention.

**FIGURES 33C-33F** are schematic side views of wire top shunts inserted into a patient's coronary artery.

15      **FIGURES 33G-33I** are schematic side views of a delivery sequence for inserting a wire top shunt.

**FIGURE 34A** is a side view of a wire top shunt according to another embodiment of the present invention.

**FIGURE 34B** is a side view of a ball top shunt according to one embodiment of the present invention, the shunt being shown laid out flat.

20      **FIGURE 34C** is a side view of the ball top shunt of **FIGURE 34B**, shown implanted in a patient.

**FIGURE 34D** is a side view of a ball top shunt according to another embodiment of the present invention, the shunt being shown laid out flat.

25      **FIGURE 34E** is a side view of a ball top shunt according to another embodiment of the present invention, the shunt being shown in its preassembly configuration.

**FIGURE 34F** is a side view of a ball top shunt according to another embodiment of the present invention, the shunt being shown laid out flat.

30      **FIGURE 34G** is a side view of the ball top shunt of **FIGURE 34F**, shown implanted in a patient.

**FIGURE 34H** is a side view of a ball top shunt according to another embodiment of the present invention, the shunt being shown laid out flat.

**FIGURE 34I** is a side view of a ball top shunt according to another embodiment of the present invention, the shunt being shown laid out flat.

**FIGURE 34J** is a side view of a ball top shunt according to another embodiment of the present invention, the shunt being shown laid out flat.

**FIGURE 34K** is a side view of a flexible ball top shunt.

5           **FIGURE 34L** is a side view of the delivery apparatus for the ball top shunt of **FIGURE 34K**.

**FIGURE 35** is a side view of a wire top shunt according to another embodiment of the present invention.

**FIGURE 36** is an enlarged view of the wire top shunt of **FIGURE 35**.

10           **FIGURE 37** is a side view of a wire top shunt according to another embodiment of the present invention.

**FIGURE 38** is a top view of the wire top shunt of **FIGURE 37**.

**FIGURES 39A-39F** are side views showing the deployment sequence of a wire top shunt.

15           **FIGURE 40A** is a side view of a flare top shunt according to one embodiment of the present invention.

**FIGURE 40B** is a side view of a flip-down shunt according to one embodiment of the present invention, the shunt being shown laid out flat.

**FIGURE 40C** is a side view of the flip-down shunt of **FIGURE 40B**, shown implanted in a patient.

20           **FIGURE 41** is a side view of a shunt with a T-flange.

**FIGURE 42** is a schematic view of a hinged conduit.

**FIGURE 43** is a schematic view of another embodiment of a hinged conduit.

**FIGURE 44A** is a schematic side view of a bell shape stent having a web flange and an axially expandable region.

25           **FIGURE 44B** is a schematic side view of the distal end of the stent of **FIGURE 44A** showing more particularly the web flange in the coronary artery.

**FIGURE 44C** is a schematic side view of the stent and web flange of **FIGURE 44A** showing a stylet holding the web flange closed.

**FIGURE 46** is a schematic side view of a conduit having annular grooves.

30           **FIGURE 47A** is a schematic side view of a conduit having a single loop anchoring mechanism.

**FIGURE 47B** is a front view of the conduit of **FIGURE 47A**.

**FIGURE 48A** is a side view of a conduit having deployable flanges.

35           **FIGURE 48B** illustrates the conduit of **FIGURE 48A** with the flanges deployed.

Detailed Description of the Preferred Embodiment

As is well known, the coronary artery branches off the aorta and is positioned along the external surface of the heart wall. The anatomy of the human heart is illustrated in FIGURE 1A. Oxygenated blood flows from the heart PH to the aorta AO, on to the rest of the body, some of the blood flowing into the coronary artery CA. In some individuals, plaque builds up within the coronary artery CA, blocking the free flow of blood and causing complications ranging from mild angina to heart attack and death.

In order to restore the flow of oxygenated blood through the coronary artery, one embodiment of the present invention provides for the shunting of blood directly from the heart to a site in the coronary artery that is distal to the blockage. A channel is formed through the wall of the coronary artery and the myocardium and into the left ventricle of the heart that lies beneath the coronary artery. A stent or conduit is positioned in the passage to keep it open, and allow for the flow of oxygenated blood directly from the heart into the coronary artery. Again, it should be understood that while the insertion of the conduit in the myocardium between the left ventricle and the coronary artery is described in detail below, this is merely exemplary and use of the conduit between other chambers of the heart and the coronary artery, and between blood vessels is also contemplated.

The principles of the present invention are not limited to left ventricular conduits, and include conduits for communicating bodily fluids from any space within a patient to another space within a patient, including any mammal. Furthermore, such fluid communication through the conduits is not limited to any particular direction of flow and can be antegrade or retrograde with respect to the normal flow of fluid. Moreover, the conduits may communicate between a bodily space and a vessel or from one vessel to another vessel (such as an artery to a vein or vice versa). Moreover, the conduits can reside in a single bodily space so as to communicate fluids from one portion of the space to another. For example, the conduits can be used to achieve a bypass within a single vessel, such as communicating blood from a proximal portion of an occluded coronary artery to a more distal portion of that same coronary artery.

In addition, the conduits and related methods can preferably traverse various intermediate destinations and are not limited to any particular flow sequence. For example, in one preferred embodiment of the present invention, the conduit communicates from the left ventricle, through the myocardium, into the pericardial

space, and then into the coronary artery. However, other preferred embodiments are disclosed, including direct transmyocardial communication from a left ventricle, through the myocardium and into the coronary artery. Thus, as emphasized above, the term "transmyocardial" should not be narrowly construed in connection with the preferred fluid communication conduits, and other non-myocardial and even non-cardiac fluid communication are preferred as well. With respect to the walls of the heart (and more specifically the term "heart wall"), the preferred conduits and related methods are capable of fluid communication through all such walls including, without limitation, the pericardium, epicardium, myocardium, endocardium, septum, etc.

The bypass which is achieved with certain preferred embodiments and related methods is not limited to a complete bypass of bodily fluid flow, but can also include a partial bypass which advantageously supplements the normal bodily blood flow. Moreover, the occlusions which are bypassed may be of a partial or complete nature, and therefore the terminology "bypass" or "occlusion" should not be construed to be limited to a complete bypass or a complete occlusion but can include partial bypass and partial occlusion as described.

The preferred conduits and related methods disclosed herein can also provide complete passages or partial passages through bodily tissues. In this regard, the conduits can comprise stents, shunts, or the like, and therefore provide a passageway or opening for bodily fluid such as blood. Moreover, the conduits are not necessarily stented or lined with a device but can comprise mere tunnels or openings formed in the tissues of the patient.

The conduits of the present invention preferably comprise both integral or one-piece conduits as well as plural sections joined together to form a continuous conduit. The present conduits can be deployed in a variety of methods consistent with sound medical practice including vascular or surgical deliveries, including minimally invasive techniques. For example, various preferred embodiments of delivery rods and associated methods may be used. In one embodiment, the delivery rod is solid and trocar-like. It may be rigid or semi-rigid and capable of penetrating the tissues of the patient and thereby form the conduit, in whole or in part, for purposes of fluid communication. In other preferred embodiments, the delivery rods may be hollow so as to form the conduits themselves (e.g., the conduits are preferably self-implanting or self-inserting) or have a conduit mounted thereon (e.g., the delivery rod is preferably withdrawn leaving the conduit installed). Thus, the

preferred conduit device and method for installation is preferably determined by appropriate patient indications in accordance with sound medical practices.

In some individuals, aortic insufficiency or peripheral venous insufficiency occurs. Aortic insufficiency is the leakage of blood through the aortic valve, resulting in a backflow of blood into the left ventricle. The heart compensates for the backflow of blood by pumping harder, resulting in hypertrophy (thickening of the heart muscle) and dilation of the left ventricle wall. Left untreated, heart failure can result. In venous insufficiency, the heart valves are unable to prevent the backflow of blood. This too can result in heart failure. Accordingly, one embodiment of the invention provides for the use of a conduit placed within the heart wall to improve the flow of oxygenated blood through the body.

#### Balloon Expanded Stent

A first embodiment of the present invention is illustrated in **FIGURE 1B**. This embodiment is a balloon-expanded stent 10. The stent 10 is introduced as described below, using a high-pressure balloon catheter 12 to deploy the stent 10 once it is properly positioned in the myocardium MYO (**FIGURE 2**). When the stent 10 is positioned inside the myocardial wall MYO, the balloon 14 is inflated to expand the stent 10 and open the conduit from the left ventricle LV into the coronary artery CA. The stent 10 can include attachment mechanisms not limited to hooks, barbs, flanges, large collars, suture holes and/or other means to ensure a seal is created between the coronary artery CA and the wall of the myocardium MYO and to prevent the threat of stent 10 migration. When the attachment of the stent 10 is completed, the remaining catheter assembly 12 is removed, leaving the stent 10 in place. Upon deflating the balloon 14, the stent 10 will remain open. Because of the shape of this stent 10, a dumbbell shaped balloon 14 is preferably used to ensure proper expansion, as described below.

**FIGURES 1B** through **4** illustrate the introduction of the balloon-expanded stent 10 into the myocardial wall MYO. **FIGURE 1B** illustrates the stent 10 mounted over the balloon 14 on the distal end of the stent introducer catheter 12. **FIGURE 2** illustrates the stent introducer catheter 12 following the path created by a puncture wire 16 extending past the distal end of the introducer catheter 12, and used to access the left ventricle LV through the coronary artery CA and myocardium MYO.

**FIGURE 3** illustrates the non-expanded stent 10 positioned inside the myocardial wall MYO prior to inflation of the balloon 14. **FIGURE 4** illustrates an

expanded stent 10 in position, with the introducer catheter 12 removed. Because of the way the attachment mechanisms 18 expand on this stent 10, a dumbbell shaped balloon 14 is preferably used to flare out the ends of the stent 10. These flared edges 18 maintain the stent 10 in its proper position in the heart wall MYO and provide a seal between the coronary artery CA and the outer heart wall MYO.

5                   Self Expanding Stent

The second embodiment of the stent or conduit incorporates a self-expanding stent 20, illustrated in **FIGURES 5-8**. The stent 20, having a retaining sheath 26 to hold it in a non-expanded configuration, is introduced into the wall of the myocardium MYO as follows. The stent delivery catheter 22 is advanced over a puncture mechanism 24 and into the wall of the myocardium MYO as described above. When the stent 20 is properly seated in the myocardial wall MYO, its retaining sheath 26 is withdrawn, allowing the stent 20 to expand and open a conduit from the ventricle LV to the coronary artery CA. This stent 20 also includes attachment mechanisms not limited to hooks, barbs, flanges, large collars, suture holes and/or other means to ensure a seal is created between the artery CA and the wall of the myocardium MYO, and to prevent the threat of stent 20 migration. When the positioning is completed, the remaining catheter assembly 22 is removed, leaving the stent 20 in place.

10                  The self-expanding stent 20 mounted on the distal end of the stent introducer catheter 22 is illustrated in **FIGURE 5**. **FIGURE 6** illustrates the stent introducer 22 following the path created by a puncture wire 24 used to form the passage between the coronary artery CA and the left ventricle LV. **FIGURE 7** illustrates a non-expanded stent 20 located in position on the stent introducer catheter 22 with the introducer catheter 22 in position in the heart wall MYO. **FIGURE 8** illustrates the self-expanding stent 20 in position, with the introducing catheter 22 removed. Flared edges 28 on the stent 20 maintain its proper position in the heart wall MYO and provide a seal between the coronary vessel CA and outer surface of the heart MYO.

15                  For the stent designs described above, additional anchoring methods may be desired to maintain the stent's proper position and/or create a leak-free seal in the coronary artery. Suitable attachment mechanisms include a set of barbs located on the stent body or flares and a collar on the coronary side to help seal and prevent blood from exiting the gap between the vessel and outer heart wall. The stent can 20 also be anchored in place by applying sutures. The stent can include holes at either

end to facilitate the placement of these anchoring sutures. A suture gun can be used to apply multiple sutures at the same time. In addition, the stents can be lined, if desired, with materials such as polymers, for example polytetrafluoroethylene (PTFE), silicone or GORETEX, to provide for the ease of blood flow therethrough.

5      Stent with Attachment Flanges

A third embodiment of the stent design, illustrated in **FIGURES 9-11**, incorporates attachment flanges or "legs" 30 that expand after introduction into the myocardium to hold the stent 34 in place. The puncture instrument 32 and stent 34 are mated together and are advanced into the myocardial wall as a single unit. The puncture instrument's distal end 36 is shaped in a "nose-cone" configuration, which is responsible for containing the legs 30 of the stent 34 while it is being introduced into the wall of the myocardium. When the stent 34 is in the proper position in the myocardial wall, the nose cone 36 is pushed forward, releasing the attachment legs 30 of the stent 34. The internal diameter (ID) of the stent 34 is large enough to allow the nose cone 36 to pass back through. The stent 34 is then released from the catheter 38 and the catheter 38 is removed.

10     **FIGURE 9** illustrates the stent 34 mounted on the introducer catheter 38. The expanding legs 30 of the stent 34 are held in place by the nose cone 36 on the distal end of the catheter 38 that acts as a dilator. The catheter assembly 38 is advanced over a puncture wire if desired, into proper position in the myocardium, and the nose cone 36 is pushed forward allowing the legs 30 to expand as shown in **FIGURE 10**. The nose-cone/puncture assembly 32, 36 is then withdrawn through the lumen of the stent 34. When the nose-cone/puncture assembly 32, 36 is removed, the stent 34 can be pushed off the introducer catheter 38 and remains in the myocardium in the position shown in **FIGURE 11**. **FIGURE 11** also illustrates a sealing collar 44 that may be used in the interface between the coronary artery and the outer wall of the heart to prevent hemorrhaging around the stent 34 and to hold the stent 34 in place. Sutures can be used to ensure that the stent is maintained in its proper position and prevent migration.

15     Biodegradable Stent

20     If desired, the stent or conduit of the present invention can be formed of biodegradable or bioabsorbable materials and/or used to deliver drugs directly into the myocardium and the coronary circulation. Such a stent 52 is illustrated in **FIGURE 13**. The biodegradable stent 52 can extend only partially through the myocardium MYO as illustrated in **FIGURE 13**, but can also extend entirely through

from the left ventricle LV to the coronary artery CA. Once positioned in the myocardium MYO, the stent 52 degrades, dissolves or is absorbed over time to release drugs, genes, angiogenesis or growth factors, or other pharmaceutical compounds directly into the heart muscle MYO and the coronary artery CA, as shown by the arrows in **FIGURE 13**. Bioabsorbable materials include, but are not limited to, polymers of the linear aliphatic polyester and glycolide families, such as polylactide and polyglycolide.

5

#### Bulkhead Stent

**FIGURE 12** illustrates a further embodiment of the present invention, a "bulkhead" stent 50. This stent 50 consists of a plurality of rings, which are placed in the myocardium MYO. The rings 50 form a passage through which blood flows from a chamber in the heart, such as the left ventricle LV, directly into the coronary artery CA. The stent 50 is preferably formed of biocompatible material such as a metal or polymer. A gun or other suitable device can be used to implant the stent 50 in the myocardium MYO.

15

If desired, the separate units or rings of the stent 50 can be connected via a wire, suture thread, or similar means. The wire is threaded through the holes 51 located in each ring. Connecting the rings of the stent 50 in this manner serves to make the stent 50 more stable and to prevent the migration of the individual units. If desired, a valve (not shown) can be incorporated into the stent 50 to help prevent the backflow of blood into the left ventricle LV.

20

25

30

35

Turning now to **FIGURES 14-26**, there is illustrated in greater detail one preferred method and apparatus for providing a bulkhead stent 50, as shown in **FIGURE 12**, into the myocardium MYO. As shown in **FIGURE 14**, a stent delivery catheter 60 is advanced over a puncture wire 62 and into the wall of the myocardium MYO as described above. The stent delivery catheter 60 follows the path created by the puncture wire 62 used to form the passage between the coronary artery CA and the left ventricle LV. **FIGURE 15** illustrates a bulkhead stent 50 still located in position inside the stent delivery catheter 60 with the catheter 60 in position in the heart wall MYO.

**FIGURES 16-19** show one embodiment for deploying the bulkhead stent 50 into the myocardium MYO. As the delivery catheter 60 is retracted proximally from the myocardium MYO, the rings comprising the bulkhead stent 50 are deployed into the myocardium MYO. **FIGURES 20 and 21** are enlarged views of **FIGURES 18**

and 19, showing the rings of the bulkhead stent 50 positioned within the myocardium MYO to form the passageway therethrough.

FIGURES 22-25 illustrate more particularly the structure and deployment of the rings comprising the bulkhead stent 50. As shown in FIGURE 24, the bulkhead stent comprises a plurality of rings 64 that are initially loaded into the delivery catheter 60. While inside the lumen of the catheter 60, each ring 64 has a loaded configuration 64A, shown in FIGURES 22 and 25. After ejection from the catheter 60, the ring 64 assumes an inserted configuration 64B, shown in FIGURES 23 and 25. Preferably, the inserted configuration of ring 64B includes a plurality of flanges 66 around the circumference of each ring 64, thereby providing a securement mechanism to anchor each ring 64 to the myocardium MYO. Each ring 64 transforms from its loaded configuration 64A to its inserted configuration 64B by virtue of being released from the catheter 60. Specifically, the catheter 60 acts as a restraint on each ring 64 to keep it in its loaded configuration 64A. Then, once the ring 64 is released from the catheter 60, the flanges 66 provided along the circumference of each ring 64 are allowed to extend outward to provide the securement mechanism.

FIGURE 26 illustrates an inserter device or handle 68 that may be used in deploying the bulkhead stent 50 into the myocardium. The inserter handle 68 preferably comprises a gun 70 with a trigger 72, and a wire 74 extending from a nozzle 76. The rings 64 (not shown) of the bulkhead stent 50 are preferably loaded onto the wire 74, and may be deployed into the myocardium preferably one at a time by pressing the trigger 72.

#### Screw Stent

FIGURES 27-30 illustrate another embodiment of the present invention. Here, a self-expanding spring or screw stent 140 is delivered into the myocardium MYO. As illustrated in FIGURE 27A, a channel 142 through the wall of the myocardium MYO is first created, as described above, using a device 144 delivered through the aorta AO and coronary artery CA. The channel 142 travels from the coronary artery CA through the myocardium MYO and into the left ventricle LV as shown in FIGURE 27B. The distal end of the stent delivery catheter 146 bearing the stent 140 is then positioned within the channel 142, as shown in FIGURE 28. Preferably, the position of the distal end of the delivery catheter 146 is checked radiographically, to ensure proper positioning. Next, as illustrated in FIGURE 29, the self-expanding spring stent 140 is delivered into the channel 142 wall of the

myocardium MYO. The stent 140 is cut such that it does not extend past the myocardium MYO and into either the left ventricle LV or the coronary artery CA. Again, the proper positioning and length of the stent 140 is preferably checked radiographically and any necessary adjustments made before the delivery catheter 146 is removed, as shown in **FIGURE 30**.

5                   Stent with Retention Members

10                  **FIGURE 31** illustrates another embodiment of the stent 200 having retention members 202. The hollow stent body 204 is held in place in the heart wall by one or more retention members 202 which are deployed after the stent 200 is properly positioned, as described above. **FIGURE 31** shows the retention members 202 in their deployed position. A flange 206 acts to seal the opening in the coronary artery, while the retention members 202 reside in the myocardium, helping to anchor the stent 200 in place.

15                  Distal Top Shunts

20                  In another embodiment, as illustrated in **FIGURE 32**, a coronary artery bypass is accomplished by disposing a left ventricular conduit 300 in a heart wall or myocardium MYO of a patient's heart PH. The conduit 300 preferably extends from the left ventricle LV of heart PH to a clogged coronary artery CA at a point downstream of a blockage BL. Conduit 300 is preferably made of a biocompatible material such as stainless steel or nitinol, although other materials such as Ti, Ti alloys, Ni alloys, Co alloys and biocompatible polymers may also be used. The conduit 300 may also be coated. The conduits described herein are further characterized by a distal top that is preferably collapsible into a first configuration and expandable into a second configuration. The collapsible and expandable characteristics of the distal top may be accomplished by using a shape memory alloy or superelastic material.

25

30                  **FIGURE 33A** illustrates a wire top shunt 300 according to one embodiment of the present invention. The shunt 300 preferably comprises an elongate tubular body 311, preferably made of NiTi, having a proximal end 312 and a distal end 314 and a lumen 316 extending therethrough. The distal end 314 corresponds to the end that opens into the coronary artery CA. The proximal end 312 as shown is joined to the distal end of second tube 320, which is preferably made of stainless steel. In one embodiment, the second tube 320 may be a sheath over the tube 312. In the embodiment shown, the shunt 310 comprises both the tubular body 311 and the tube 320, with the proximal end of tube 320 (not shown) opening into the left ventricle. The diameter change from tube 312 to tube 320 allows for a smooth transition from

35

the unsheathed section of the shunt to the sheathed section. The step between the two tubes also provides a mechanical stop for the shunt which is used to transmit axial force from the sheathed section to the shunt during insertion.

Wire loops 318 are preferably attached to the distal end 314 to form the distal top. The wire loops preferably form a generally ball-shaped configuration, with the diameter of the ball corresponding approximately with the diameter of the artery. When implanted, the wire loops 318 are preferably located in the coronary artery CA to hold the shunt therein. The wire loops 318 preferably expand beyond the diameter of the tubular body. Therefore, these loops are preferably collapsible such that they can be inserted into a delivery tube, as described below.

Although **FIGURE 33A** illustrates a design with two loops, it will be appreciated that multiple designs with different numbers of loops and other configurations are possible. Moreover, loops having different shapes, such as hoops, arches, etc., are also contemplated. Furthermore, wires of different sizes may be used. The wire loops 318 and the tubular body 311 may also be integrally formed from a single piece of material and laser cut into the desired configuration. **FIGURE 33B** illustrates another embodiment having folded down loops 318. In this embodiment the shunt 310 has a proximal end 312 which itself opens into the left ventricle when implanted. The proximal end 312 is pointed to assist in inserting the shunt 310 through the heart wall, as described below.

**FIGURES 33C-33F** illustrate different embodiments of a loop top shunt implanted in a patient. More particularly, the proximal end (not shown) of the conduit preferably extends into the left ventricle, and the distal end having loops 318 extends into the coronary artery. The loops 318 of each of these embodiments are preferably sized to open against the walls of the coronary artery CA, as shown.

**FIGURES 33G-33I** illustrate one preferred delivery sequence of a shunt having wire loops 318. It will be appreciated that this delivery method can be applied to other types of shunts, such as the shunts described below. As shown in **FIGURE 33G**, a delivery sheath 326 is placed over the loops 318 to restrain the loops into a collapsed configuration. An optional stylet 327 may also be used to restrain the loops. In this configuration the shunt is implanted into a heart wall, with the loops 318 (located within the sheath 326) being positioned in a coronary artery CA. As shown in **FIGURE 33H**, the sheath 326 is removed, allowing the loops 318 to expand outward. As shown in **FIGURE 33I**, when the sheath 326 is fully

removed, the loops 318 assume an expanded configuration against the walls of the coronary artery CA.

5       **FIGURE 34A** illustrates another embodiment of a shunt 310. In this embodiment, the tubular body 311 is preferably made of NiTi, and preferably has a proximal end 312 which itself opens into the left ventricle when implanted. The shunt 310 of **FIGURE 34A** has a pointed tip 312 to assist in inserting the shunt 310 through the heart wall, as described below. The distal top in this embodiment is a wire top 322, preferably integrally formed with the tubular body 311, and is to be implanted into the coronary artery CA. The wire top 322 preferably comprises a plurality of wire segments that form generally a ball shape. The shape and size of the ball can be varied to conform to a range of artery sizes. Like the embodiment of  
10      **FIGURES 32A-32F**, the wire top 322 can be collapsed for insertion into the body, and expanded like a stent to position the shunt 310, more particularly the wire top 322, in the artery.

15      **FIGURES 34B-34I** illustrate several other embodiments of ball top stents, particularly showing wire tops 322 having various configurations. Furthermore, the shunts 310 illustrated in **FIGURES 34B-34G** are formed such that near proximal end 312 the shunt has a solid portion 313, and between solid portion 313 and wire top 322 the shunt 310 substantially comprises a wire frame 311. The wire frame 311 gives the shunt 310 flexibility to bend into curved configurations. This wire frame is preferably laser cut from a solid piece of tubing, though other methods of manufacture may also be used. **FIGURES 34H-34J** illustrates shunts 310 having substantially solid body constructions, with pointed proximal ends 312.

20      **FIGURE 34K** illustrates one embodiment of a shunt 310 having a solid proximal portion 313, a flexible portion 311 and a wire top or ball top 322. **FIGURE 34L** illustrates a delivery system used to delivery the shunt 310 of **FIGURE 34K**. A stylet 372 is inserted through the shunt 310. The stylet 372 as shown may be curved, and because the portion 311 of the shunt is flexible, the shunt 310 also curves. A sleeve 374 extends over the distal top 322 to hold the top in a collapsed configuration. The arrangement as shown in **FIGURE 34L** is inserted into the patient's heart wall, preferably through the coronary artery, through the heart wall and into the left ventricle. The distal top 322 is arranged such that it is located within the coronary artery. The sleeve 374 is removed to expand the distal top 322 in the coronary artery.

5

**FIGURES 35 and 36** illustrate enlarged views of a shunt 310 with a wire top 322, where the wire top 322 is preferably integrally formed. As can be seen, the wire top 322 preferably uses a four strut design, wherein the tubular body 311 at the distal end 314 transitions into four wires 324 forming the wire top 322. This embodiment is more preferably referred to as a knob top design.

**FIGURES 37 and 38** illustrate another embodiment wherein the shunt of **FIGURES 35 and 36** instead have a flat top design.

10

**FIGURES 39A-39F** illustrate a preferred deployment sequence of a conduit 310 having a wire top 322. The shunt 310 is preferably inserted into the delivery tube 326, distal end first, such that the wire top 322 is inserted into the tube 326 and is collapsed therein. As shown in **FIGURE 39A**, the delivery tube preferably has a bulged region 328 for receiving the wire top 322 when in its collapsed configuration. The bulged region 328 gives the operator tactile feedback for sensing when the sheath is in the proper position for deployment. The arrangement shown in **FIGURE 39A**, in one embodiment, is inserted into the heart with the proximal end of the shunt 310 extending into the left ventricle and the distal end of the shunt extending into the coronary artery. With the shunt 310 in position, the delivery tube is retracted, as shown in **FIGURES 39B-39F** from the shunt to release the wire top 322 into its expanded configuration in the coronary artery.

15

**FIGURE 40A** illustrates another embodiment of a shunt 310 having a flare top 330. The shunt illustrated in **FIGURE 40A** has six flares extending from distal end 314 and integrally formed therewith. It will be appreciated that fewer or more flares may be provided, and that these flares may extend away from the shunt body 311 at various angles to hold the shunt within the coronary artery. These flares are preferably collapsible to allow the shunt to be inserted into a delivery tube such as described above. **FIGURES 40B and 40C** illustrate a flip-down shunt having sections 332 which fold down when implanted in a patient to anchor the shunt to the artery CA. This shunt 310, as illustrated, has a wire portion 311 and a solid portion 313.

20

**FIGURE 41** illustrates another embodiment of a shunt 310. The shunt 310 has a proximal end 312 and a distal end 314, the proximal end preferably having an opening for receiving blood from the left ventricle. The distal end also has an opening for delivering blood from the left ventricle to the coronary artery. The shunt 310 shown in **FIGURE 41** preferably has a T-flange 376 at the distal end.

When implanted, this T-flange preferably is positioned on the outside of the heart, and holes 378 are used to suture the device to the heart wall.

Hinged Conduit

Additional embodiments include conduits which are engaged and aligned with the left ventricle and the coronary artery in the patient's heart. **FIGURE 42** illustrates a conduit 420 for connecting the left ventricle LV to the coronary artery CA. The conduit 420 comprises a solid tube that has a cut section 422 that can be bent over to align with the artery CA.

**FIGURE 43** illustrates a conduit 424 similar to the conduit of **FIGURE 42**, which is more preferably a nitinol stent having a short hinged section 426 to align with the coronary artery.

Bell-Shape Conduit

**FIGURES 44A** and **44B** illustrate an alternate embodiment of a conduit 428 between the left ventricle and coronary artery which is preferably a nitinol stent. The proximal end 430 of the stent opening into the left ventricle preferably is heat set to have a bell shape to hold to the interior heart wall and to introduce flow. The distal end 432 preferably has small heat set fingers 434 which extend outward to anchor the stent against the interior wall of the coronary artery. A web flange 436 on the distal end 432 preferably comprises two or more rings which, when placed in the heart, open in the coronary artery to position the conduit while allowing blood flow. These rings are preferably shaped to extend outward in a curved configuration as shown in **FIGURE 44A** when deployed. Between the proximal and distal ends is an axially expandable region 438, provided by slots 440 cut in the region.

**FIGURE 44C** illustrates a stylet 442 used for inserting a conduit 428 having the web flange 436 shown in **FIGURES 44A** and **44B**. More particularly, the stylet 442 is inserted through the rings of the web flange 436 to bring the rings together or closed for insertion. Removal of the stylet 442 after the conduit 428 is placed in the heart allows the rings to expand outward to the shape shown in **FIGURES 44A** and **44B**.

Conduit Having Annular Grooves

**FIGURE 46** illustrates an embodiment where the conduit is provided with annular grooves. Grooves may also be provided longitudinally along the conduit. The raised or protruding portions on the outer surface of the conduit are imbedded into the heart wall to anchor the conduit in place, thereby preventing migration of the conduit after it is placed between the left ventricle and the coronary artery.

Single Loop Conduit

FIGURES 47A and 47B illustrate an alternative embodiment of a conduit 500, having a single loop 502 (similar to a basket handle) used to anchor the conduit 500 in the coronary artery CA. The conduit 500 is preferably a one-piece construction formed from a nitinol tube. The loop 502 can be heat formed, such that it conforms to the inner wall of the coronary artery CA. The loop 502 includes flexure regions 504 which provide elasticity. The elasticity allows the conduit 500 to accommodate artery constriction and variation in the internal diameter of the artery. The loop 502 provides axial and radial support to prevent migration of the conduit 500.

10

Conduit with Rotating Sheath and Deployable Flanges

15

20

25

30

FIGURES 48A and 48B illustrate yet another embodiment of a conduit 510, having deployable flanges 514 used to anchor the conduit 510 in place. The conduit 510 includes a sheath 516 which is rotatable, and flanges 514 that include spring arms 512. The sheath 516 has windows 518 through which the flanges 514 are deployed. Prior to positioning in the body, the sheath 516 is positioned on the conduit 510 so as to retain the flanges 514. After the conduit 510 is properly positioned, the sheath 516 is rotated such that the windows 518 are aligned with the flanges 514. The spring arms 514 cause the flanges 514 to be deployed through the windows 518 following rotation of the retaining sheath 516, thus anchoring the conduit 510 in its proper position. It should be noted that no axial rotation is required to deploy the flanges 514.

25

30

It should be appreciated that the stents and conduits described above, and particularly the bulkhead stent, are useful in other applications in addition to stenting the myocardium. For example, these stents may also serve as other types of coronary stents, arterial or venous stents, as well as biliary and esophageal stents.


30

The present vascular shunt provides significant improvements in the present treatment of blockages in the coronary artery. Although the invention has been described in its preferred embodiments in connection with the particular figures, it is not intended that this description should be limited in any way.

WHAT IS CLAIMED IS:

1. A bypass conduit for use in a wall of heart, comprising:
  - a hollow conduit having an interior and an exterior and adapted to be positioned in the heart wall between the coronary artery and a chamber in the heart, wherein the conduit has an attachment mechanism on at least one end adapted to anchor the conduit in place.
- 5 2. The device of Claim 1, wherein the conduit is self-expandable.
3. The device of Claim 1, wherein the conduit is expanded using an inflatable balloon.
- 10 4. The device of Claim 1, wherein the chamber is the left ventricle.
5. The device of Claim 1, wherein the attachment mechanism is selected from the group consisting of hooks, barbs, flanges, collars, suture holes, and expandable legs.
- 15 6. The device of Claim 1, wherein the conduit is comprised of a plurality of circular rings.
7. The device of Claim 6, wherein the rings are reversibly connected to one another.
8. The device of Claim 1, wherein the conduit is biodegradable.
9. The device of Claim 1, wherein the conduit is bioabsorbable.
- 20 10. The device of Claim 9, wherein the conduit is used to deliver pharmaceutical compounds directly into the heart wall.
11. The device of Claim 1, further comprising a valve positioned within the interior of the conduit.
- 25 12. The device of Claim 1, wherein the attachment mechanism is adapted to anchor the conduit in the heart wall.
13. The device of Claim 1, wherein the attachment mechanism is adapted to anchor the conduit in the coronary artery.
14. The device of Claim 1, wherein the attachment mechanism comprises a distal top that is collapsible into a first configuration and expandable into a second configuration, the distal top when expanded being sized and configured to hold the top within the blood vessel.
- 30

1/55



**FIG. 1A**

2/55




FIG. 1B

3/55




FIG. 2

4/55




FIG. 3

5/55




FIG. 4

6/55




FIG. 5

7/55




FIG. 6

8/55




FIG. 7

9/55









FIG. 8



11/55

**FIG. 11**

12/55

**FIG. 12****FIG. 13**

13/55




FIG. 14

14/55




FIG. 15

15/55




FIG. 16

16/55




FIG. 17

17/55




FIG. 18

18/55






FIG. 19

19/55





**FIG. 20**


20/55

**FIG. 21**

21/55

**FIG. 22****FIG. 23****FIG. 24**

22/55

**FIG. 25**









FIG. 26

24/55


**FIG. 27A****FIG. 27B**

**FIG. 28****FIG. 29**


26/55

**FIG. 30**


27/55

**FIG. 31**


28/55

**FIG. 32**




29/55

**FIG. 33A**





30/55

**FIG. 33B**


31/55

**FIG. 33C****FIG. 33D****FIG. 33E**

32/55



**FIG. 33F****FIG. 33G****FIG. 33H****FIG. 33I**

33/55




**FIG. 34A**


34/55

**FIG. 34B****FIG. 34C**


35/55


**FIG. 34D**

36/55


**FIG. 34E**

37/55


**FIG. 34F**



**FIG. 34H**  
SUBSTITUTE SHEET (RULE 26)





**FIG. 34I**  
SUBSTITUTE SHEET (RULE 26)




**FIG. 34J**  
SUBSTITUTE SHEET (RULE 26)


41/55

**FIG. 34K****FIG. 34L**

42/55





**FIG. 35**






**FIG. 36**




43/55

**FIG. 37****FIG. 38**


44/55

**FIG. 39A****FIG. 39B****FIG. 39C**


45/55

**FIG. 39D****FIG. 39E****FIG. 39F**


46/55

**FIG. 40A**


47/55

**FIG. 40B**


48/55

**FIG. 41**

49/55

**FIG. 42**

50/55



**FIG. 43**

51/55






FIG. 44A

52/55




**FIG. 44B**





**FIG. 44C**

53/55





*FIG. 46*

54/55

**FIG. 47A****FIG. 47B**

55/55

**FIG. 48A****FIG. 48B**

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/US 99/20714

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 08456 A (TRANSVASCULAR INC) 5 March 1998 (1998-03-05) figures 1-8 page 12, line 26 -page 14, line 6 page 30, line 35 -page 33, line 13 ---	1-5, 11-13
X	US 5 429 144 A (WILK PETER J) 4 July 1995 (1995-07-04) figures 7-9 column 5, line 43 - line 65 column 8, line 1 - line 58 ---	1,3-5,11
X	US 5 655 548 A (SHMULEWITZ ASCHER ET AL) 12 August 1997 (1997-08-12) figures 4-6 column 6, line 7 -column 7, line 6 ---	1,4,5,11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

**Special categories of cited documents :**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "3" document member of the same patent family

Date of the actual completion of the international search

12 January 2000

Date of mailing of the international search report

21/01/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Mary, C

# INTERNATIONAL SEARCH REPORT

Interr	al Application No
	PCT/US 99/20714

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 5 935 119 A (GUY THOMAS D ET AL) 10 August 1999 (1999-08-10) figures 1-5 column 2, line 43 - line 58 column 3, line 28 - line 40 ---	1,2
P,X	WO 99 36001 A (HEARTSTENT CORP) 22 July 1999 (1999-07-22) page 3, line 3 - line 29 page 4, line 5 - line 24 ---	1,4,5, 11.12
X	WO 97 32551 A (ENERGY LIFE SYSTEMS CORP) 12 September 1997 (1997-09-12) figures 1-6 page 5, line 2 -page 6, line 2 page 7, line 12 - line 26 ---	1
P,X	WO 99 21510 A (KENSEY NASH CORP) 6 May 1999 (1999-05-06) figures 1,9,10 page 13, line 7 -page 14, line 6 page 19, line 14 -page 22, line 7 -----	1,2,4-6, 8-10
A		7

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte-	Application No
PCT/US 99/20714	


Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9808456	A 05-03-1998	AU 4234097	A	19-03-1998
US 5429144	A 04-07-1995	US 5409019	A	25-04-1995
		US 5287861	A	22-02-1995
US 5655548	A 12-08-1997	AU 4352497	A	02-04-1998
		WO 9810714	A	19-03-1998
		US 5824071	A	20-10-1998
US 5935119	A 10-08-1999	NONE		
WO 9936001	A 22-07-1999	AU 2324299	A	02-08-1999
WO 9732551	A 12-09-1997	US 5810836	A	22-09-1998
		EP 0891172	A	20-01-1998
		US 5971993	A	26-10-1999
		US 5878751	A	09-03-1999
WO 9921510	A 06-05-1999	US 5980548	A	09-11-1999
		AU 1079599	A	17-05-1999



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :	A1	(11) International Publication Number: <b>WO 00/15147</b>
<b>A61F 2/06</b>		(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number:	PCT/US99/20714	
(22) International Filing Date:	10 September 1999 (10.09.99)	
(30) Priority Data:		1111 Crestview Way, Goshen, KY 40026 (US). GRIFFIN, Mark [US/US]; Apartment 3, 4113 Bridgewood Court, Louisville, KY 40241 (US). WOLF, Scott, J. [US/US]; 2501 Irvine Avenue South, Minneapolis, MN 55405 (US). WILK, Peter, J. [US/US]; 185 West End Avenue, New York, NY 10023 (US). SCHMELTER, Jay, W. [US/US]; 6090 Annapolis Lane North, Plymouth, MN 55466 (US). FURNISH, Simon, M. [US/US]; 2429 Longest Avenue, Louisville, KY 40204 (US). RENATI, Richard, J. [US/US]; * (US). MELSKY, Gerald [US/US]; * (US). GUILES, Marvin [US/US]; * (US).
60/099,767	10 September 1998 (10.09.98)	US
60/104,397	15 October 1998 (15.10.98)	US
60/147,202	4 August 1999 (04.08.99)	US
60/147,218	4 August 1999 (04.08.99)	US
09/369,048	4 August 1999 (04.08.99)	US
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application		(74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, LLP, Sixteenth Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).
US	09/369,048 (CIP)	
Filed on	4 August 1999 (04.08.99)	
(71) Applicant (for all designated States except US): PERCARDIA, INC. [US/US]; Suite 434, 20 Trafalgar Square, Nashua, NH 03063 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(72) Inventors; and		
(75) Inventors/Applicants (for US only): PHELPS, David, Y. [US/US]; 904 Shady Lane, Louisville, KY 40223 (US). FURNISH, Greg, R. [US/US]; 2614 Top Hill Road, Louisville, KY 40206 (US). HALL, Todd, A. [US/US];		
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TRANSMYCARDIAL SHUNT AND ITS ATTACHMENT MECHANISM, FOR LEFT VENTRICULAR REVASCULARIZATION



## (57) Abstract

A conduit is provided to provide a bypass around a blockage in the coronary artery. The conduit is adapted to be positioned in the myocardium or heart wall to provide a passage for blood to flow between a chamber of the heart such as the left ventricle and the coronary artery, distal to the blockage. The stent is self-expanding or uses a balloon to expand the stent in the heart wall. Various attachment means are provided to anchor the stent and prevent its migration. In one embodiment, a conduit is provided having a distal top which is more preferably a ball top, wire top, flare top or flip-down top. These top configurations anchor the shunt at one end in the coronary artery.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						